%0 Journal Article %A Miriam Barrecheguren %A Mónica Monteagudo %A Jaume Ferrer %A Eulalia Borrell %A Carles Llor %A Marc Miravitlles %T “Treatment patterns in the newly diagnosed COPD patients in Catalonia between 2007-2012” %D 2014 %J European Respiratory Journal %P P1457 %V 44 %N Suppl 58 %X Introduction:Initial treatment patterns in the newly diagnosed COPD patient usually don´t follow current clinical guidelines.Methods:Epidemiological study with data obtained from the Information System for Development in Research in Primary Care (SIDIAP), a population database that contains information of 5.8 million of habitants (80% of Catalonia´s population). Newly diagnosed COPD patients in 2007-2012 were identified through a diagnostic algorithm and information about the initial treatment patterns was collected.Results:During the study period, 40863 patients were diagnosed of COPD with an incidence rate of 18 cases per 10000 person/year.32606 were men(79.8%) with a mean age of 66.05 years(SD 11.49).44% had spirometric confirmation. As a first treatment, 18575 (45.5%) were prescribed inhaled corticosteroids ICs, 17626 (42.1%) were on long acting b-adrenergic agonists (LABA), 11519 (28.2%) short acting b-adrenergic agonists (SABA), 10008 (24.5%) short acting muscarinic antagonists (SAMA), 9758 (23.9%) patients were treated with long acting muscarinic antagonists (LAMA), and. 7353 patients (18%) received no treatment after diagnosis.Between 2007 and 2012 the use of bronchodilators (LAMA, LABA and LABA/LAMA) doubled (from 6% to 11.4%, 4.6% to 8.87% and from 1.06% to 3.73% respectively). There were little or no changes in the use of LABA + ICS (24.6% to 21.7%) and triple therapy (11.3% to 12%). Patients receiving no treatment decreased from 20.6% to 13.4%.Conclusions:ICs are frequently prescribed as a first treatment for newly diagnosed COPD patients. The use of bronchodilators alone has increased but still represents a small part of initial treatments.Study funded by Novartis Spain. %U